mots-c with retatrutide Buy Metabolic Stack UK | + Retatrutide + MOTS-c | Elite

Phase 2 Clinical Data (NEJM, 2023) The landmark Phase 2 Retatrutide trial (NEJM, June 2023) is the primary clinical evidence base for researcher interest in this compound

Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, not a pure GLP-1 agent

[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Vosoughi K, Salman Roghani R, Camilleri M

Some weeks feel stronger than others but the overall effect remains solid

With muscle preservation during GLP-1 therapy being a major concern, retatrutide's glucagon component is of particular interest

a figure that many patients on GLP-1 therapy fall short of, partly because the appetite suppression the medications produce makes hitting protein targets without conscious effort difficult. Clinical note Patients on GLP-1 therapy frequently report that protein-rich foods (particularly meat and eggs) become less palatable during treatment